

rates: transmission from infected animals to persons clandestinely engaging in ritual slaughter; specifically, an Ethiopian Jewish community. Physicians in countries receiving immigrants should be aware of ceremonial practices that place patients at risk for zoonoses. The severe respiratory manifestations that ensued following aerosol exposure to animal blood or secretions suggest that brucellosis with pulmonary involvement after inhalation of *Brucella*-infected aerosols might be more common than previously documented.

References

1. Shemesh A, Yagupsky P. Increasing incidence of human brucellosis in southern Israel after the cessation of a veterinarian control campaign. *Air Water Borne Diseases*. 2013;2:112. <http://www.omicsgroup.org/journals/increasing-incidence-of-human-brucellosis-in-southern-israel-after-the-cessation-of-a-veterinarian-control-campaign-2167-7719.1000112.php?aid=17444>
2. Brucellosis—Israel (02): (Hadarom) melitensis, bovine, human. ProMED-mail. 2015 31 Oct [cited 2015 Oct 31]. <http://www.promedmail.org>, archive no. 20151031.3757610.
3. Eales KM, Norton RE, Ketheesan N. Short report: brucellosis in northern Australia. *Am J Trop Med Hyg*. 2010;83:876–8. <http://dx.doi.org/10.4269/ajtmh.2010.10-0237>
4. Al Dahouk S, Neubauer H, Hensel A, Sconeberg I, Nockler K, Alpers K, et al. Changing epidemiology of human brucellosis, Germany 1962–2005. *Emerg Infect Dis*. 2007;13:1895–900. <http://dx.doi.org/10.3201/eid1312.070527>
5. Salomon H. Blood between the Beta Israel and their Christian neighbours in Ethiopia—key symbols in an inter-group context [article in Hebrew]. *Jerusalem Studies in Jewish Folklore*. Mandel Institute for Jewish Studies. 1993 [cited 2015 Jan 6]. <http://www.jstor.org/stable/23356293>
6. Rosenber R, Vinker S, Zakut H, Kizner F, Nakar S, Kitai E. An unusually high prevalence of asthma in Ethiopian immigrants to Israel. *Fam Med*. 1999;31:276–9.
7. Henning LN, Miller SM, Pak DH, Lindsay A, Fisher DA, Barnewell R, et al. Pathophysiology of the rhesus macaque model for inhalational brucellosis. *Infect Immun*. 2012;80:298–310. <http://dx.doi.org/10.1128/IAI.05878-11>
8. Theegarten D, Albrecht S, Totsch M, Teschler H, Neubauer H, Al Dahouk S. Brucellosis of the lung: case report and review of the literature. *Virchows Arch*. 2008;452:97–101. <http://dx.doi.org/10.1007/s00428-007-0518-0>
9. Nabukenya I, Kaddu-Mulindwa D, Nasinyama G. Survey of *Brucella* infection and malaria among abattoir workers in Kampala and Mbarara districts, Uganda. *BMC Public Health*. 2013;13:901. <http://dx.doi.org/10.1186/1471-2458-13-901>

Address for correspondence: Inbal Fuchs, Clalit Health Services—Infectious Diseases, 17 Shlomo Hamelech, Beer Sheva 85545, Israel; email: fuksen@bgu.ac.il, inbalfp@gmail.com

Follow-up of Ebola Patient, 2014–2015

Venkatesh Srinivas, Pragya Yadav, Veena Mittal, Gouri Chaubal, Mala Chhabra, Sanjay Mattoo, Arvind Rai, Devendra T. Mourya

Author affiliations: National Centre for Disease Control, New Delhi, India (S. Venkatesh, V. Mittal, M. Chhabra, A. Rai); National Institute of Virology, Pune, India (P. Yadav, G. Chaubal, D.T. Mourya); Airport Authority of India, New Delhi (S. Matto)

DOI: <http://dx.doi.org/10.3201/eid2204.151405>

To the Editor: The 2014–2015 epidemic of Ebola virus disease (EVD) in West Africa affected 23,666 persons and caused 14,603 deaths (1). The World Health Organization (WHO) declared the epidemic a public health emergency (2). Although Ebola virus is transmitted by unprotected physical contact with infected persons, published reports about which body fluids are infected or the risk for fomite transmission are few (3). For most cases, virus was detected by reverse transcription PCR (RT-PCR) of clinical (saliva, feces, semen, breast milk, tears, nasal blood, skin swab) and environmental specimens (4). Earlier reports of the follow-up of recovered patients stated that viral RNA was detected by RT-PCR for up to 33 days in vaginal, rectal, and conjunctival swab samples from 1 patient and up to 101 days in seminal fluid from 4 patients. Infectious virus was detected in 1 seminal fluid sample 82 days after disease onset (4,5).

Attendees at the Eighth Meeting of the WHO Advisory Group on the EVD Response (1) discussed potential risk factors, including hidden chains of transmission and sexual transmission, and determined the following criteria. A country can declare “interruption of transmission” when 42 days have elapsed since the last diagnosis of a case. A country can declare that the “outbreak has stopped” when test results from the last case are negative twice or after another 90-day interval. For determining a cutoff for finally declaring the strategy and criteria for elimination, extensive follow-up on infectivity of semen in Ebola survivors is needed.

We report follow-up of a man who recovered from EVD and was monitored for 165 days after he was declared Ebola-free. The 26-year-old man from India returned to New Delhi, India, from Liberia on November 10, 2014, with a certificate from the government of Liberia stating that he was “cured” of Ebola. Because EVD is considered an exotic disease in India, he was placed in isolation at the Airport Health Organization quarantine center at Indira Gandhi International Airport, New Delhi (6). Serum and semen samples were collected and sent to the National Centre for Disease Control (NCDC), New Delhi, and the National Institute of Virology (NIV), Pune, India. The serum was negative by

Table. Results of attempted real-time RT-PCR and virus isolation from semen of Ebola virus disease survivor, 2014–2015*

Sample no.	Days declared Ebola-free†	RT-PCR C _t		Cell lines used for virus isolation	Passage								
		NCDC‡	NIV§		1		2		3		4		
					CPE	C _t	CPE	C _t	CPE	C _t	CPE	C _t	
1	45	17	22.5	Vero CCL81	None	28.5	None	None	None	None	None	None	None
				Vero E6	None	31.5	None	None	None	None	None	ND	None
2	64	21	24	Vero CCL81	None	None	None	None	None	None	None	ND	ND
				Vero E6	None	32.5	None	None	None	None	None	ND	ND
3¶	77	22	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
4¶	98	26	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
5¶	111	27	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
6	125	30	34	Vero CCL81	None	None	None	None	ND	ND	ND	ND	ND
				Vero E6	None	None	None	None	ND	ND	ND	ND	ND
7	141	28	38	Vero CCL81	None	None	None	None	ND	ND	ND	ND	ND
				Vero E6	None	None	None	None	ND	ND	ND	ND	ND
8	165	28	35.0	Vero CCL81	None	None	None	None	ND	ND	ND	ND	ND
				BHK-21	None	None	None	None	ND	ND	ND	ND	ND

*C_t, cycle threshold; CPE, cytopathic effect; NA, not applicable; NCDC, National Centre for Disease Control, New Delhi, India; ND, not done; NIV, National Institute of Virology, Pune, India; RT-PCR, reverse transcription PCR.

†Primers from <http://www.crcf.sn/wp-content/uploads/2014/09/CDC-Ebola-International-Lab.pdf>.

‡Primers from the Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

§Primers from (7).

¶Samples received at NCDC only.

real-time RT-PCR ([7]; <http://www.cdc.gov/vhf/ebola/diagnosis/index.htm>) and positive (titer 1:400) by IgG ELISA (8). However, the semen was positive for Ebola viral RNA by real-time RT-PCR. A viral RNA extraction kit (QIAGEN, Valencia, CA, USA) was used to extract RNA from samples. Real-time RT-PCRs were set up in a Bio-Rad real-time PCR machine (Model C1000 Touch CFX96; Hercules, CA, USA) by using a SuperScript III Platinum One-Step qRT-PCR kit with ROX (Invitrogen, Carlsbad, CA, USA).

As a confirmatory measure, partial nucleoprotein gene (1216 nt), partial viral protein (VP) gene (337 nt), and the intergenic region near the VP gene along with VP polyA tail (383 nt) from the semen sample were amplified by RT-PCR (9). These sequences (GenBank accession nos. KT191140–KT191142) showed 100% similarity with *Zaire ebolavirus* isolate EBOV/DML14077/SLe/WesternUrban/20150630. To avoid cross-contamination, we used a γ -inactivated Ebola Reston virus strain as a positive control. The RT-PCRs were set up in a Bio-Rad thermal cycler (C1000) by using SuperScript III One-Step RT-PCR System with Platinum-Taq-DNA-Polymerase (Invitrogen).

Ebola virus isolation attempts were made from the semen sample in VeroE6 cells, Vero CCL81, *Pipistrellus* bat embryo, and BHK-21 cell lines at NIV. No isolate was obtained. Cycle thresholds of 28.5 and 31.5 were observed in Vero CCL81 and Vero E6 cells, respectively, in the first passage by real time RT-PCR, but no virus or cytopathic effect was detected in the subsequent 2 passages (Table).

According to WHO guidelines, the semen sample was transported from NCDC to a Biosafety Level 4 laboratory at NIV (for virus isolation). At the time of inoculation in cell culture, the sample had been subjected to a single freeze–thaw cycle. The sensitive nature of the virus may be why Ebola virus was not isolated. PCR positivity alone is

not sufficient for considering a patient infectious for Ebola; however, because EVD is considered an exotic disease in India, we depended on real-time RT-PCR–based data for establishing EVD positivity.

Follow-up semen samples were positive by real time RT-PCR for up to 165 days after the patient was declared Ebola-free and were negative thereafter. Cycle thresholds of samples tested at NIV were 22.5 on day 45 after being declared Ebola-free, 24 on day 64, 34 on day 125, 38 on day 141, and 35.0 on day 165 (Table).

Clear criteria for elimination and declaration of the end of an outbreak are needed because any misinterpretation or miscommunication among the countries could negatively affect community confidence (10). Although we monitored the patient for 165 days, monitoring began \approx 10 days after the patient had recovered. Ebola viral RNA persistence has been documented in a human semen sample for up to 10 months after the patient was declared Ebola-free (11). According to the data from this study, the current elimination period may need to be extended, and further studies on the infectivity of semen samples from recovered EVD patients are warranted.

Acknowledgment

We gratefully acknowledge the encouragement and support extended by the Secretary, Government of India, Department of Health Research; Director General, Indian Council of Medical Research, New Delhi; and Rashmi Arora, for support in conducting this study. We extend our thanks and gratitude toward workers of the integrated diseases surveillance program for their cooperation with this study. We also thank Rajen Lakra, Prasad Sarkale, Prasad Kokate, Deepak Patil, Yosman Rajendran, and Anila Rajendran for technical support.

Financial support was provided by Indian Government Ministry of Health and Family Welfare.

References

1. World Health Organization. Eighth Meeting of the WHO Advisory Group on the EVD Response; 2015 Mar 20; Geneva. Geneva: The Organization; 2015 [cited 2015 Mar 25]. <http://www.who.int/csr/disease/ebola/advisory-groups/8th-meeting-report.pdf?ua=1>
2. World Health Organization. WHO Statement on the Meeting of the International Health Regulations Emergency Committee Regarding the 2014 Ebola Outbreak in West Africa; 2014 Aug 8; Geneva. Geneva: The Organization; 2014 [cited 2014 Nov 3]. <http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/>
3. Osterholm MT, Moore KA, Kelley NS, Brosseau LM, Wong G, Murphy FA, et al. Transmission of Ebola viruses: what we know and what we do not know. *mBio*. 2015;6 [cited 2016 Jan 19]. <http://dx.doi.org/10.1128/mBio.00137-15>
4. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. *J Infect Dis*. 2007;196(Suppl 2):S142–7. <http://dx.doi.org/10.1086/520545>
5. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis*. 1999;179(Suppl 1):S170–6. <http://dx.doi.org/10.1086/514291>
6. ProMEDmail. Ebola virus disease—ex Africa (39): India, worldwide susp. or quarantined. 2014 Nov 18 [cited 2015 Dec 23]. <http://www.promedmail.org.archive.no.20141118.2966874>
7. Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. *J Infect Dis*. 2007;196(Suppl 2):S205–12. <http://dx.doi.org/10.1086/520601>
8. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel M, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis*. 1999;179(Suppl 1):S177–87. <http://dx.doi.org/10.1086/514321>
9. Drosten C, Götting S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. *J Clin Microbiol*. 2002;40:2323–30. <http://dx.doi.org/10.1128/JCM.40.7.2323-2330.2002>
10. O'Dempsey T, Khan SH, Bausch DG. Rethinking the discharge policy for Ebola convalescents in an accelerating epidemic. *Am J Trop Med Hyg*. 2015;92:238–9. <http://dx.doi.org/10.4269/ajtmh.14-0719>
11. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C et al. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. *N Engl J Med*. 2015 Oct 14 [cited 2015 Oct 20]. <http://dx.doi.org/10.1056/NEJMoa1511410>

Address for correspondence: Devendra T. Mourya, National Institute of Virology, Pune, 20-A, Dr. Ambedkar Rd, Pune (Maharashtra), Pin 411001, India; email: dtmourya@gmail.com, directorniv@gmail.com

Sustained Elevated Cytokine Levels during Recovery Phase of Mayaro Virus Infection

Dennis Tappe, José Vicente Pérez-Girón, Gudrun Just-Nübling, Gernot Schuster, Sergio Gómez-Medina, Stephan Günther, César Muñoz-Fontela, Jonas Schmidt-Chanasit

Author affiliations: Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (D. Tappe, S. Günther, C. Muñoz-Fontela, J. Schmidt-Chanasit); German Centre for Infection Research, Hamburg (D. Tappe, S. Günther, C. Muñoz-Fontela, J. Schmidt-Chanasit); Leibniz Institute for Experimental Virology, Hamburg (J. Vicente Pérez-Girón, S. Gómez-Medina, C. Muñoz-Fontela); J.W. Goethe University Center for Infectious and Tropical Diseases, Frankfurt, Germany (G. Just-Nübling); Praxis Schuster, Reinhardshagen, Germany (G. Schuster)

DOI: <http://dx.doi.org/10.3201/eid2204.151502>

To the Editor: Mayaro virus (MAYV), a mosquito-borne alphavirus endemic to South America, causes a self-limiting febrile arthralgia syndrome closely resembling Chikungunya fever (*1*). MAYV has been detected increasingly as imported infections in international travelers returning to Europe and North America (*2–9*). Joint pain, the most prominent symptom, is often long-lasting (several months), sometimes incapacitating (*4,6,7,9*), and may recur (*8*). Arthralgia develops during the acute phase and symmetrically affects the wrists, ankles, and small joints of hands and feet. Joint swelling may occur initially, but permanent joint damage has not been described (*5*). The clinical disease and diagnostic procedures have been described (*1–9*), but immunologic parameters and their possible role in the clinical follow-up of patients (i.e., during the postacute long-lasting arthralgia period) remain to be investigated.

To further our knowledge of MAYV infection, we analyzed cytokine levels in serum samples from 6 travelers to South America who returned to Europe with Mayaro fever (MF). Two of the cases occurred during 2014; 4 occurred during 2011–2013 (*2–5*).

The 6 travelers comprised 2 men and 4 women who were 20–54 (median 36) years of age (online Technical Appendix Table, <http://wwwnc.cdc.gov/EID/article/22/4/15-1502-Techapp1.pdf>). The 2 most recent cases occurred in spring 2014 in a 28-year-old female student and a 54-year-old male physician. Serologic testing was performed for both patients at the Bernhard Nocht Institute and confirmed by virus neutralization testing (*4*).

The student had traveled for 3 weeks in Ecuador, visiting rainforest villages and hiking in the jungle. During her